Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN 24 FE vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Prevention of pregnancy,Moderate acne vulgaris (in females ≥15 years who have onset of menarche and desire an oral contraceptive for contraception)
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
One tablet (20 mcg ethinyl estradiol / 1 mg norethindrone acetate) orally once daily for 24 days, followed by 1 iron-containing placebo tablet (75 mg ferrous fumarate) orally once daily for 4 days.
One tablet orally once daily for 28 consecutive days per cycle.
Ethinyl estradiol: ~13 hours (range 7–20); norethindrone: ~8 hours (range 5–14). Half-life supports once-daily dosing; steady state achieved within 5–7 days.
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism in liver and gut wall, sulfation and glucuronidation. Norethindrone: primarily hepatic reduction and conjugation; metabolized via CYP3A4 and CYP2C9.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Ethinyl estradiol: 40% renal, 60% fecal; norethindrone: 40% renal, 60% fecal.
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
Ethinyl estradiol: 98% bound to albumin and SHBG; norethindrone: 93% bound to albumin and SHBG.
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
Ethinyl estradiol: 2.3–4.0 L/kg; norethindrone: 3.0–4.5 L/kg. Indicates extensive tissue distribution.
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Ethinyl estradiol: ~45% (range 38–48%); norethindrone: ~65% (range 60–70%). First-pass metabolism reduces oral bioavailability.
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
No specific dose adjustment recommended; use with caution in patients with renal impairment. No GFR-based guidelines established.
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Contraindicated in patients with hepatic adenomas, acute hepatitis, or decompensated cirrhosis (Child-Pugh class B or C). No dose adjustment recommended in mild hepatic impairment (Child-Pugh class A) but use with caution.
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Safety and efficacy established for use after menarche; dose same as adult: one active tablet daily for 24 days then one placebo tablet daily for 4 days. No weight-based dosing.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
Not indicated for postmenopausal women; no specific dose adjustment recommended, but consider increased risk of thromboembolic events and cardiovascular disease in older women.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction, thromboembolism) from oral contraceptive use. Risk increases with age and number of cigarettes smoked, particularly in women >35 years. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thromboembolic disorders (e.g., DVT, PE, stroke, MI),Cigarette smoking (increases cardiovascular risk),Hypertension,Gallbladder disease,Hepatic neoplasia (liver tumors),Carbohydrate/lipid metabolism effects (hyperglycemia, hypertriglyceridemia),Headache (including migraine),Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Depression,Pregnancy and postpartum use,Lactation (may reduce milk production)
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenomas or carcinomas,Known or suspected hypersensitivity to any component of the product,Heavy smoking (>15 cigarettes/day) and age >35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
No significant food interactions. Grapefruit juice may increase estrogen levels, but effect is minimal. Take with food if nausea occurs.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
LARIN 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on epidemiological data, but there is a small increased risk of cardiovascular defects. Second and third trimester exposure may cause fetal harm, including feminization of male fetuses (mild hypospadias) and potential for other teratogenic effects. Use is not recommended during pregnancy.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Combined hormonal contraceptives like LARIN 24 FE are generally not recommended during breastfeeding due to potential suppression of milk production and excretion of small amounts of hormones into breast milk. The M/P ratio is not well established; estrogens and progestins are present in milk at low concentrations. Use in lactating women should be avoided, especially in early postpartum period. Alternative contraception methods are preferred.
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
No dose adjustments are applicable as LARIN 24 FE is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (increased clearance of steroids) are not relevant due to contraindication. Therapy should be discontinued immediately if pregnancy occurs.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
LARIN 24 FE is a combined hormonal contraceptive containing ethinyl estradiol and norethindrone. It uses a 24/4 regimen with 24 active pills and 4 iron-containing placebo pills. The iron (ferrous fumarate) in placebo pills is not contraceptive and serves to reduce iron-deficiency anemia risk. Prescribe for contraception, acne, or menstrual disorders. Monitor for VTE risk, especially in smokers over 35. Consider drug interactions with CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) which reduce efficacy. Breakthrough bleeding is common in the first 3 cycles.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
Take one pill daily at the same time; missing pills increases pregnancy risk.,Active pills are light blue; placebo pills are brown and contain iron.,Use backup contraception for the first 7 days if starting after Day 5 of menstrual cycle.,If you miss two or more active pills, take the last missed pill and use backup contraception for 7 days.,Smoking while on this pill increases risk of serious cardiovascular side effects; do not smoke.,Report signs of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or vision changes.,Iron in placebo pills helps prevent anemia but does not provide contraception.
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN 24 FE vs DEMULEN 1/50-28, answered by our medical review team.
LARIN 24 FE is a Combination Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN 24 FE and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN 24 FE is: One tablet (20 mcg ethinyl estradiol / 1 mg norethindrone acetate) orally once daily for 24 days, followed by 1 iron-containing placebo tablet (75 mg ferrous fumarate) orally once daily for 4 days.. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN 24 FE and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN 24 FE is classified as Category C. LARIN 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on epidemiological data, bu. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.